RecruitingNCT06309979
A Study to Assess Growth in Children With Idiopathic Short Stature
A Multicenter, Observational Study to Characterize Growth in Children With Idiopathic Short Stature
Sponsor
BioMarin Pharmaceutical
Enrollment
300 participants
Start Date
Aug 8, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.
Eligibility
Min Age: 2 YearsMax Age: 16 Years
Inclusion Criteria5
- Participants must be > 2 years old, and ≤ 14 years old (female) or ≤ 16 years old (males) at the time of signing the informed consent.
- A height assessment corresponding to a height Z-score of ≤ -2.25 SDs in reference to the general population of the same age and sex, as calculated using the Centers for Disease Control and Prevention (CDC) growth chart (https://www.cdc.gov/growthcharts/zscore.htm).
- Participants who have either never received hGH, or who are currently receiving hGH treatment.
- Historic stimulation test result with serum or plasma GH level greater than 10 μg/L.
- Parent(s) or guardian(s) are willing and able to provide written, signed informed consent.
Exclusion Criteria6
- Diagnosis of systemic disease or condition that may cause short stature, eg renal, neoplastic, pulmonary, cardiac, gastrointestinal, immunologic and metabolic disease. Children with such diagnoses can be considered for inclusion if their condition is well controlled, at the discretion of the Medical Monitor.
- Known presence of one or more pituitary hormone deficiencies
- Bone age advanced over chronological age by more than 3 years.
- For hGH naïve participants, historic stimulation test result with serum or plasma GH level greater than 10 μg/L or serum IGF-1 in the normal range for age (between -1.00 SDs and +2.00 SDs).
- For participants currently on hGH treatment, historic results before GH treatment of stimulation test with serum or plasma GH level greater than 10 μg/L or serum IGF-1 test between -1.00 SDs and +2.00 SDs.
- Have received an investigational product (IP) or investigational medical device for any purpose within 6 months before the Screening visit. .
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(40)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06309979
Related Trials
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
NCT0722185111 locations
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
NCT0638215547 locations
The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature
NCT0692731038 locations
Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
NCT047986901 location
Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
NCT016043951 location